Replies to post #25718 on Al Capone's Vault

[BottomBounce]

$VVUS VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union. The company offers Qsymia, a drug for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II clinical studies for the treatment of obstructive sleep apnea and diabetes. The company has an agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California. http://finance.yahoo.com/q/pr?s=VVUS+Profile

[BottomBounce]

$MJNA Today, there are 23 states (and Washington, D.C.) that have legalized medical marijuana, and four states -- Oregon, Washington, Colorado, and Alaska (plus Washington, D.C.) -- that have legalized the drug across the board. For some consumers, marijuana offers to alleviate their chronic or terminal symptoms, while for states, it's an avenue to generate more tax revenue that can be used to fund education, create or retain jobs, or help close budget gaps. Long Live $MJNA

[BottomBounce]

$AMRS The consensus price target (PT) of $2.80 means that the market expects Company shares to increase by 526.19% in the short run.